CALISIANT Trademark

Trademark Overview


On Thursday, February 25, 2016, a trademark application was filed for CALISIANT with the United States Patent and Trademark Office. The USPTO has given the CALISIANT trademark a serial number of 86920161. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Tuesday, June 30, 2020. This trademark is owned by Allergan Sales, LLC. The CALISIANT trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the ...
calisiant

General Information


Serial Number86920161
Word MarkCALISIANT
Filing DateThursday, February 25, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateTuesday, June 30, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 18, 2017

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Translation of Words in MarkThe wording "CALISIANT" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 1, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Tuesday, June 30, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, June 30, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, December 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 5, 2019EXTENSION 5 GRANTED
Tuesday, December 3, 2019EXTENSION 5 FILED
Thursday, December 5, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, December 3, 2019TEAS EXTENSION RECEIVED
Tuesday, March 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 15, 2019EXTENSION 4 GRANTED
Friday, March 15, 2019EXTENSION 4 FILED
Friday, March 15, 2019TEAS EXTENSION RECEIVED
Saturday, November 3, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 1, 2018EXTENSION 3 GRANTED
Thursday, November 1, 2018EXTENSION 3 FILED
Thursday, November 1, 2018TEAS EXTENSION RECEIVED
Thursday, June 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 5, 2018EXTENSION 2 GRANTED
Tuesday, June 5, 2018EXTENSION 2 FILED
Tuesday, June 5, 2018TEAS EXTENSION RECEIVED
Friday, November 17, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 15, 2017EXTENSION 1 GRANTED
Wednesday, November 15, 2017EXTENSION 1 FILED
Wednesday, November 15, 2017TEAS EXTENSION RECEIVED
Tuesday, June 13, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 18, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 18, 2017PUBLISHED FOR OPPOSITION
Wednesday, March 29, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, March 16, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, March 3, 2017ASSIGNED TO LIE
Friday, February 10, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 10, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 10, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 1, 2017ASSIGNED TO LIE
Saturday, January 14, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 13, 2017NOTICE OF REVIVAL - E-MAILED
Thursday, January 12, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 12, 2017PETITION TO REVIVE-GRANTED
Thursday, January 12, 2017TEAS PETITION TO REVIVE RECEIVED
Thursday, December 22, 2016ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, December 21, 2016ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, May 25, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 25, 2016NON-FINAL ACTION E-MAILED
Wednesday, May 25, 2016NON-FINAL ACTION WRITTEN
Wednesday, May 25, 2016ASSIGNED TO EXAMINER
Tuesday, March 1, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, February 29, 2016NEW APPLICATION ENTERED IN TRAM